35 results about "Arteriole smooth muscle" patented technology

A method and system for determination and mapping the quantity of chromophores having a distinct spectrum attached to moving objects in an spectrally rich environment that may include multiple chromophores attached to stationary objects. An area of inters is imaged at different times and different wavelengths, and the spectral properties of the or more chromophores attached to the moving objects are separated from the stationary spectral properties of the background, followed by spectral analysis of the moving objects to determine their quantity. Application to the retinal vasculature is illustrated, showing the imaging, analyzing and quantifying of the oxygen saturation of retinal blood, resolved for the different vascular compartments—capillaries, arterioles, venules, arteries, and veins. Changes in the structure of the vascular environment are also determined, whether growth of new vessels or the elimination of existing ones, by the generation of path maps based on analysis of differential images taken at a single wavelength of the moving components in the blood flow.

Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidney, the heart, and the central and peripheral nervous systems, (iv) plaque rupture of atheromatous lesions of major blood vessels such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the fermoral arteries and the popliteal arteries, (v) diabetes or the complications of diabetes.

To provide an embolic material excision trapping device capable of excising an embolic material in an arteriole or vessel without blocking the blood flow, and further, trapping the material with reliability. A device for removing an embolic material in a lumen in a living body has a long shaft member 1 having a front end and a base end and sending the front end to a distal end of the lumen, a filter member 5 which is provided on the front-end side of the shaft member 1, and contracts linearly inside a catheter for carrying the device while expanding when released into the lumen from the catheter, and a coil member 7 which is provided in the shaft member 1 on the side closer to the base-end side than the filter member 5, and contracts linearly inside the catheter while expanding spirally when released into the lumen from the catheter, where the coil member 7 destroys and traps an embolic material in the lumen, and the filter member 5 traps an liberated piece of the embolic material.

The present invention relates to the unexpected finding that vessels smaller than even the smallest arteries (i.e. arterioles) thicken, become dysfunctional and cause end organ damage to tissues as diverse as the brain and the kidney. This invention provides a method to improve the structure and function of arterioles and preserve the function of end organs such as the brain and kidney.

A method and system for determination and mapping the quantity of chromophores having a distinct spectrum attached to moving objects in an spectrally rich environment that may include multiple chromophores attached to stationary objects. An area of inters is imaged at different times and different wavelengths, and the spectral properties of the or more chromophores attached to the moving objects are separated from the stationary spectral properties of the background, followed by spectral analysis of the moving objects to determine their quantity. Application to the retinal vasculature is illustrated, showing the imaging, analyzing and quantifying of the oxygen saturation of retinal blood, resolved for the different vascular compartments—capillaries, arterioles, venules, arteries, and veins. Changes in the structure of the vascular environment are also determined, whether growth of new vessels or the elimination of existing ones, by the generation of path maps based on analysis of differential images taken at a single wavelength of the moving components in the blood flow.

Disclosed are A₃ adenosine receptor antagonists and/or partial agonists of formula (I): wherein R¹ to R⁵ are as described herein, as well as pharmaceutical compositions thereof and methods of use thereof. The antagonists or partial agonists find use in treating a number of diseases including cancer, glaucoma, inflammatory diseases, asthma, stroke, myocardial infarction, allergic reactions, rhinitis, poison ivy induced responses, urticaria, scleroderma, arthritis, brain arteriole diameter constriction, bronchoconstriction, and myocardial ischemia, as well as in preventing cardiac ischemia. Also disclosed are radiolabeled compounds of formula (I) and the use thereof in diagnostic imaging of tissues and organs.

Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with a colony stimulating factor (CSF) or a nucleic acid molecule encoding a CSF. Furthermore, the use of a CSF or a nucleic acid molecule encoding a CSF for the preparation of pharmaceutical compositions for enhancing neovascularization and/or collateral growth of collateral arteries and/or other arteries from preexisting arteriolar connections is described. Also provided are methods for the treatment of tumors comprising contacting an organ, tissue or cells with an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through the inhibition of the biological activity of CSFs. Described is further the use of an agent which suppresses neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections through inhibition of the biological activity of CSFs for the preparation of pharmaceutical compositions for the treatment of tumors.

The invention belongs to the field of the medical application of a lauromacrogol injection, and particularly relates to application of a lauromacrogol injection as a medicament for treating internal hemorrhoid. Internal hemorrhoid is one of hemorrhoids, which occurs above the pectinate line of the anal canal and is a commonly encountered disease having the highest incidence rate among the hemorrhoids; for majorities of people, internal hemorrhoid bleeding is a disease difficult to deal with; and when the internal hemorrhoid bleeds too much, secondary anemia can be caused. In the invention, the lauromacrogol injection is injected into the hemorrhoid, so that an aseptic inflammation is produced and is then gradually fiberized, thus realizing the treatment of the internal hemorrhoid. The lauromacrogol injection can wrap veins and arterioles in the hemorrhoid, so that a protective layer can be formed at the peripheries of the veins and arterioles, thereby preventing weak blood vessels from bleeding due to damage caused by defecation and other factors; fiber textures can occlude blood vessel cavities, eliminate or lessen the expansion and congestion of the veins and atrophy the hemorrhoid; because of the fiberization process, a relaxed mucous membrane can be fixed on the muscular wall thereunder again through the fiber textures, thereby eliminating the symptom.

The present invention relates to the use of a plasmid encoding a fibroblast growth factor as therapeutic agent for the prevention and treatment of hypercholesterolemia or diabetes associated myocardial or skeletal angiogenic defects. The present invention also relates to a method for enhancing formation of both collateral blood vessels and arterioles in myocardial or skeletal ischemic tissues in a mammalian subject suffering from hypercholesterolemia or diabetes. The present invention further relates to a method of promoting collateral blood vessels in ischemic myocardial or skeletal tissues without inducing VEGF-A factor expression and causing edema in the treated muscles.

The invention which belongs to medical instrument techmology field involving a preparation method of hemostasis tiedan that can absorb fibrous protein.This method is that adding the roboflavin,fibrinogen and thrombin freeze dry powder according to certain proportion into the mortar,then add anhydrous ethanol to the mortar and stirring into uniform distribution suspension,then put the uniform distribution into the flat chassis to make the surface of adhesive olynthus contact,at last,the adhesive olynhus which adhesion of mixed dry powder particle is vacuumized and drying disinfected.The hemostasis tiedan that mentioned in this invention is good at the body biocompatibility and can be degradated in vivo thoroughly.This hemostasis tiedan which is combined with the biochemical hemostasis and mechanical hemostasis can not only rein up capillary permeability blood,also can rein up the arterioles and vein hemorrhage,so that expanding the range of the clinical application greatly and this hemostasis tiedan can be used to hemostasis of visceral operation and large body surface trauma.Also,this hemostasis tiedan increase the function of drug release and partial administration by adding antibiotics and anticancer drug in the glue olynthus.

This relates to systems and methods for determining one or more of a user's physiological signals. The one or more of the user's physiological signals can be determined by measuring pulsatile blood volume changes. Motion artifacts included in the signals can be canceled or reduced by measuring non-pulsatile blood volume changes and adjusting the signal to account for the non-pulsatile blood information. Non-pulsatile blood volume changes can be measured using at least one set of light emitter-light sensor. The light emitter can be located in close proximity (e.g., less than or equal to 1mm away) to the light sensor, thereby limiting light emitted by the light emitter to blood volume without interacting with one or more blood vessels and/or arterioles. In some examples, the systems can further include an accelerometer configured to measure the user's acceleration, and the acceleration signal can be additionally be used for compensating for motion artifacts.

The invention relates to a medicine for treating chilblain. The medicine is prepared by taking pearl cream, Vaseline, starch, talcum powder or distilled water as a substrate and preparing following raw medicines into an ointment or liquid according to mass percentage: 0.1-5% of anisodamine and 0.1-5% of nitrendipine. With the adoption of the medicine for treating the chilblain, the anisodamine is taken as a blood vessel active medicine and has an expansion functions on arterioles, venule and blood capillaries, so that microcirculation can be improved; the nitrendipine is used as a calcium ion antagonist and has a selective expansion function on the venule of the peripheral blood vessels; and the anisodamine and nitrendipine are combined to have obvious improvement on blood supply of a chilblain part, so as to have the effect of preventing and treating the chilblain.

A percutaneous picking of liquestrazine free alkali for preventing thrombocyte coagulation, expanding arteriole and improving microcirculation is composed of storage layer, adhesive layer, release controlling film, substrate and protecting layer. Its advantages are stable concentration of medicine in blood, sure curative effect and low by-effect.

Disclosed herein is an apparatus and method which are used to improve blood flow in small vessels such as arterioles and capillaries. Method embodiments of the present invention make use of very high frequency (typically 1 MHZ to 100 MHZ) electrical signals in combination with ultrasonic signals typically falling within the same frequency range, where the frequency of the electrical signals and the ultrasonic signals may be the same or different. The electrical signals and ultrasonic signals are applied to a patient simultaneously, typically at a single contact location which is proximate on the exterior of the body to the arterioles and capillaries where blood flow is impaired.

The invention relates to a medical teaching aid, in particular to the manufacture of simulated subcutaneous tissue used for simulating skin of high-simulation human body model and TPE and other thermoplastic elastic bodies for simulating muscles, a skeleton is formed by using hard PVC and a 10% X-ray contrast agent mould and is provided with a simulated bone marrow cavity, and a metaphyseal end isprovided with simulated cancellous bone; the skeleton can be developed on an X-ray film without metal artifacts; the limbs on one side are made into various fractures with fracture lines/sections andare provided with a full-automatic blood circulation simulator for simulating the connection of arterioles; a simulated joint dislocation is made on the other side of the limbs without fracture; thefirst aid of limbs fracture can be fixed by a small splint, external fixation such as small splint and the like can be adopted after the fracture is manually restored, and complicated fracture can betreated by internal fixation of operation, so that the injured artery has lifelike small artery jet bleeding during the operation; the model can be used for carrying out various orthopedic operationssuch as bone traction, reduction of joint dislocation and the like, the model is used for carrying out orthopedic emergency treatment and various orthopedic operation skills training on medical students in the department of bone injuries in medical colleges and hospitals, and the teaching effect is obviously improved.

The invention discloses a series of 3-(1H-indazole)-tetrahydropyrimidine-2-one compounds (represented as the general formula I), a preparation method, and a medicinal application thereof. The novel 3-(1H-indazole)-tetrahydropyrimidine-2-one compounds have effects of inhibiting activity of Rho kinase, have the functions of relaxing aorta vessels, brain base arteriole and mesenteric vessels and protecting vascular function and pharmacological effects of promoting consumption of glucose in cells. These novel compounds have important applications in the field of preparing medicines used for preventing and/or treating cardia-cerebrovascular diseases such as hypertension, atherosclerosis, cerebral angiospasm, coronarospasm, myocardial infarction, cardiac failure, diabetes and the like, and diabetes as well as complications thereof, such as diabetic cardiovascular complication, diabetic cerebro-vascular complication and the like.

The invention relates to a hematodialysis concentrate for improving the residual renal function. The hematodialysis concentrate comprises a hematodialysis concentrate and drugs for promoting blood circulation and removing stasis, and the drugs are ligustrazine, vinpocetine or nimodipine. The hematodialysis concentrate inhibits tubular atrophy and proliferation of fibrous tissues and promotes reversion of disused nephron, improves the blood flow and increases the excretion rate of the renal tubule and the fibrous protein solution, improves blood flow volume of internal arteriovenous fistula, protects the lifeline of a hemodialysis patient, and improves the residual renal function of the residual renal function. The drugs directly permeate to a blood zone from a dialysate zone of a dialyzerin each dialysis treatment and play the roles in preventing platelet aggregation and reducing viscosity of blood in the blood zone, so that a hollow fiber of the dialyzer and a micropore of a dialysismembrane are not easy to block, the effective area for dialysis is kept, the micropore of the dialysis membrane is kept smooth, and the metabolic waste in the blood zone is fully dialyzed and cleared. The hematodialysis concentrate has the functions and effects of expanding arteriole and improving microcirculation and the renal function, and the residual nephron is protected, and the function isimproved.

The invention discloses an application of betaine in preparation of medicines for treatment of pulmonary arterial hypertension. A test result proves that in a safety dose range, the betaine, in the dosage of 400 mg/kg, can significantly improve average pulmonary arterial pressure and right ventricular systolic pressure, reduce remodeling of right ventricular and arteriole in lung and solve inflammatory response in lung tissue of adult rats. The invention proves that the betaine has treatment effects on the pulmonary arterial hypertension.

The invention relates to a traditional Chinese medicine formulation, in particular to a medicine formulation for treating hyperosteogeny by promoting blood circulation and removing blood stasis, The formulation has the functions of increasing cerebrovascular flow, reducing vascular resistance, improving cerebral blood supply and microcirculation, expanding blood vessels and arteriole, reducing blood viscosity, preventing thrombosis and dissolving thrombus for treating hyperosteogeny, in particular cervical vertebra hyperosteogeny; and can obviously improve dysfunction caused by ischemia. The medicine of the formulation can be taken orally or externally used. If people soak feet in the medicine decocted with water every day, the efficacy can be more remarkable.

The invention discloses a method for preparing specific vascular smooth muscle cells and vascular endothelial cells of CADASIL patients. The method for preparing a CADASIL disease cell model providedby the invention comprises the following steps: a) reprogramming in vitro fibroblasts from a CADASIL patient carrying NOTCH3 gene heterozygous mutation, thereby acquiring an induced pluripotent stem cell line; b) directionally differentiating the induced pluripotent stem cell line into vascular wall cells, thereby acquiring the CADASIL disease cell model. According to the invention, a reprogramming technique and a directional differentiation technique are utilized to in vitro acquire the specific induced pluripotent stem cells of CADASIL patients, the specific induced pluripotent stem cells are directionally differentiated into vascular smooth muscle cells (VSMC) and vascular endothelial cells (VEC) which are used for researching pathogenesis of CADASIL arteriole lesion, and a platform issupplied for drug screening.

The invention discloses application of ibrutinib in preparation of drugs for treating chronic hypoxic pulmonary hypertension. The experimental result shows that rising of right ventricular pressure can be significantly alleviated by using the ibrutinib to treat rats in a hypoxic group, an HE staining result shows that the thickness increasing degree of pulmonary artery medial membranes of the ratsin the hypoxic group treated by the ibrutinib is alleviated, and the number of muscularized arterioles is decreased significantly. The ibrutinib can provide a potential treatment prospect for treatment of the chronic hypoxic pulmonary hypertension.

The invention belongs to the technical field of traditional Chinese medicine, in particular to a traditional Chinese medicine composition for treating the hemorrhagic stroke. The traditional Chinese medicine composition is prepared from the following raw medicine materials in parts by weight: 3-10 parts of pseudo-ginseng, 3-10 parts of cattail pollen, 3-10 parts of rhizoma bletillae, 3-6 parts of carbonized hair, 2-5 parts of scorpion, 3-10 parts of rhizoma gastrodiae, 10-15 parts of uncaria rhynchophylla, 15-20 parts of sea-ear shell, 10-15 parts of chrysanthemum, 1-3 parts of antelope horn, 1.5-6 parts of arisaema cum bile and 10-15 parts of plantain seed. The composition has the double regulating effects of stopping bleeding and dissolving stasis, not only can stop bleeding without stasis, but also can dissolve the stasis without bleeding, thereby effectively making up for the defect that western medicine is easy to cause thrombus during stopping bleeding. The composition is used for the auxiliary treatment of the hemorrhagic stroke caused by cerebral arteriole bleeding because of high blood pressure, cerebral arteriosclerosis, cerebral arteritis, cerebral bottom aneurysm or cerebral artery and vein deformity, and the like and has unexpected good effect.